Clinical development of mTOR inhibitors: A focus on lymphoma

Reviews on Recent Clinical Trials

Volumn 2, Issue 2, 2007, Pages 103-110

  Smith, Sonali M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Clinical trials; mTOR; mTOR inhibitors; Non Hodgkin lymphoma; Pharmacokinetics; Rapamycin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; AP 23573; CCI 79; CYTOTOXIC AGENT; DEXAMETHASONE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMMUNE; RAPAMYCIN; RITUXIMAB; TEMSIROLIMUS; TORISEL; UNCLASSIFIED DRUG; WORTMANNIN;

ANAPLASTIC CARCINOMA; ANOREXIA; ASTHENIA; BONE MARROW SUPPRESSION; CANCER REGRESSION; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG TOXICITY; LYMPHADENOPATHY; LYMPHOCYTOSIS; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MOUTH ULCER; MUCOSA INFLAMMATION; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOMES RESEARCH; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TRANSLATION REGULATION;

ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA; PROTEIN KINASES; SIROLIMUS;

EID: 34248641157     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488707780599366     Document Type: Review

References (82)

1. Peng T, Golub TR, Sabatini DM. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002; 22(15): 5575-84.
2. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124(3): 471-84.
3. Hui AS, Bauer AL, Striet JB, Schnell PO, Czyzyk-Krzeska MF. Calcium signaling stimulates translation of HIF-alpha during hypoxia. FASEB J 2006; 20(3): 466-75.
4. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006; 66(11): 5549-54.
5. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006; 8(5): 394-401.
6. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35(3 Suppl): 7S-14S.
7. Banaszynski LA, Liu CW, Wandless TJ. Characterization of the FKBP.rapamycin.FRB ternary complex. J Am Chem Soc 2005; 127(13):4715-21.
8. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5(8): 671-88.
9. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23(18): 3151-71.
10. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18(16): 1926-45.
11. Proud CG. The multifaceted role of mTOR in cellular stress responses. DNA Repair (Amst) 2004; 3(8-9): 927-34.
12. Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006; 12(3 Pt 1): 679-89.
13. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004; 22(20): 4217-26.
14. Choo AY, Blenis J. TORgeting oncogene addiction for cancer therapy. Cancer Cell 2006; 9(2): 77-9.
15. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22(14): 2954-63.
16. Wendel HG, Malina A, Zhao Z, et al. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 2006; 66(15): 7639-46.
17. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 1999; 253(1): 100-9.
18. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer 2003; 3(3): 179-92.
19. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005; 433(7025): 477-80.
20. Li S, Takasu T, Perlman DM, et al. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003; 278(5): 3015-22.
21. Topisirovic I, Guzman ML, McConnell MJ, et al. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 2003; 23(24): 8992-9002.
22. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428(6980): 332-7.
23. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110(2): 177-89.
24. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110(2): 163-75.
25. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14(14): 1296-302.
26. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307(5712): 1098-101.
27. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66(3): 1500-8.
28. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65(16): 7052-8.
29. Sarbassov dos D, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22(2): 159-68.
30. Tabernero J, Rojo F, Burris H, et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inbibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors. JCO 2005: Abstract 3007.
31. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23(23): 5347-56.
32. Cancer Facts and Figures: 2006. American Cancer Society Atlanta. 2006: www.cancer.org/docroot.
33. Wlodarski P, Kasprzycka M, Liu X, et al. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 2005; 65(17): 7800-8.
34. Ruggero, D, Montanaro, L, Ma L, et al. The translation factor eIF4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10(5): 484-6.
35. Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001; 61(5): 2194-9.
36. Wall M, Poortinga G, Cardozo D, Johnstone RW, McArthur G. Inhibiton of mTOR by RAD001 Restores Normal B Cell Differentiation and Prevents B Cell Lymphomas in Eμ-MYC Mice. Blood 2006; 108(11): Abstract 2498.
37. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 2006; 25(7): 998-1007.
38. Wiestner A, Tehrani M, Chiorazzi M, et al. Point mutations and genomic deletions in Cyclin D1 create stable truncated mRNAs that are associated with increased proliferation rate and shorter survival in mantle cell lymphoma. Blood 2007 Feb 13, [Epub ahead of print].
39. Haritunians T, Mori A, O'Kelly J, Giles FJ, Koeffler HP. Antiproliferative Activity of RAD001 as a single-agent and combined with other agents in Mantle Cell Lymphoma. Am Assoc Can Res 2006: 2197 abstract.
40. Peponi E, Drakos E, Reyes G, Leventaki, V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006; 169(6): 2171-80.
41. Rudelius M, Pittaluga S, Nishizuka S, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006; 108(5): 1668-76.
42. Peponi E, Drakos e, Reyes G, Leventaki V, Medeiros LJ. Inhibition of Akt/ mTOR signalling pathway induces cell cycle arrest and apoptosis in mantle cell lymphoma. Blood 2005; 106: abstract 2415.
43. Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 2002; 20(17): 3691-702.
44. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006; 66(13): 6589-97.
45. Lim MS, Seiler C, Tripp S, Perkins SL, Cairo MS, Elenitoba-Johnson KS. Constitutive Activation of FRAP/mTOR Pathway in Pediatric Anaplastic Large Cell Lymphomas: Potential Role as a Therapeutic Target. Blood 2006; 108: abstract 290.
46. Staber PB, Vesely P, Ott R, et al. NPM-ALK Fusion Tyrosine Kinase of Anaplastic Large Cell Lymphoma Exerts Its Transforming Potential by Increasing Translation of JUNB through mTOR and S6K1. Blood 2006; 108(11): abstract 1448.
47. Funato K, Haq N, Sun SY, et al. Translational Regulation of Gene Expression by the NPM-ALK Fusion Kinase of Anaplastic Large Cell Lymphoma: A Global Evaluation of Differentially Recruited mRNA's to Polyribosomes. Blood 2006; 108(11): Abstract 291.
48. Leseux L, Hamdi SM, Al Saati T, et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006; 108(13): 4156-62.
49. Gulmann C, Espina V, Petricoin E, 3rd, et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 2005; 11 (16): 5847-55.
50. Wanner K, Hipp S, Oelsner M, et al. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br J Haematol 2006; 134(5): 475-84.
51. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16(4): 525-37.
52. Buhaescu I, Izzedine H, Covic A. Sirolimus-challenging current perspectives. Ther Drug Monit 2006; 28(5): 577-84.
53. Lebbe C, Euvrard S, Barrou B, et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006; 6(9): 2164-8.
54. Weenink JJ, Groeneveld JO, de Fijter CW. Sirolimus monotherapy for Kaposi's sarcoma in an HIV-negative patient. Lancet Oncol 2006; 7(10): 875-6.
55. Hymes LC, Warshaw BL. Sirolimus in pediatric patients: results in the first 6 months post-renal transplant. Pediatr Transplant 2005; 9(4): 520-2.
56. Garcia VD, Bonamigo Filho JL, Neumann J, et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003; 16(3): 202-6.
57. Garber K. Rapamycin may prevent post-transplant lymphoma. J Natl Cancer Inst 2001; 93(20): 1519.
58. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80(7): 883-9.
59. Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779. Drugs RD 2004; 5(6): 363-7.
60. Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006; 12(19): 5755-63.
61. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22(12): 2336-47.
62. Ansell SM, Geyer SM, Kurtin P, et al. Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group JCO 2006; 24(18S): Abstract 7532.
63. Smith SM, Pro B, Smith S, et al. Molecular Inhibition of mTOR with Temsirolimus (TORISEL, CCI-779) is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium. Blood 2006; 108: abstract 2483.
64. Chapman TM, Perry CM. Everolimus. Drugs 2004; 64(8): 861-72; discussion 73-4.
65. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43(2): 83-95.
66. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Allison MJ, Schmouder RL. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005; 60(4): 434-7.
67. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005; 45(5): 514-8.
68. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL. Effect of multiple-dose erythromycin on everolimus pharmacokinetics. Eur J Clin Pharmacol 2005; 61(1): 35-8.
69. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64(1): 252-61.
70. O'Donnell A, Faivre S, Judson C, et al. A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours Proc Am Soc Clin Oncol 2003; 22(Abstract 803).
71. Desai AA, Mita M, Fetterly GJ, et al. Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor. JCO 2005; 23(16S): abstract 3043.
72. Rivera M, Kreisberg JI, Mita MM, et al. Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. JCO 2005; 23(16S): 3033.
73. Rizzieri DA, Feldman E, Moore JO, et al. A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. Blood 2005; 106(11): abstract 2980.
74. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006; 17(5): 487-94.
75. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4(12): 988-1004.
76. Breslin EM, White PC, Shore AM, Clement M, Brennan P. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br J Pharmacol 2005; 144(6): 791-800.
77. Ikezoe T, Nishioka C, Bandobashi K, et al. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 2006; Sep 26: [Epub ahead of print].
78. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002; 9(2): 99-100.
79. Calastretti A, Rancati F, Ceriani MC, Asnaghi L, Canti G, Nicolin A. Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect. Eur J Cancer 2001; 37(16):2121-8.
80. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10(6): 594-601.
81. Yan H, Frost P, Shi Y, et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 2006; 66(4): 2305-13.
82. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12(17): 5165-73.